IKCEST

Positively aware : the monthly journal of the Test Positive Aware Network | Vol.9, Issue.5 | | Pages 18

Oral treatment for KS.

Abstract

Ligand Pharmaceuticals is seeking approval from the FDA for Panrentin (alitretinoin) gel. This drug would be the first topical treatment for Kaposi sarcoma (KS). The drug is also being studied in capsule form for oral administration. In a recent study of 34 people treated for 15 weeks, 62 percent showed a response. In seven men whose KS was unresponsive to chemotherapy, five responded to the capsules. Contact information is provided.

Original Text (This is the original text for your reference.)

Oral treatment for KS.

+More

Keywords

drug KS FDA approval Panrentin people weeks percent Contact information

Cite this article

APA

MLA

Chicago

.Oral treatment for KS.. 9 (5),18.

Disclaimer: The translated content is provided by third-party translation service providers, and IKCEST shall not assume any responsibility for the accuracy and legality of the content.